Formula I Compounds for Flaviviridae Viral Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Flaviviridae virus infections, such as those caused by hepatitis C virus, are inadequate due to high viral production and mutability, leading to limited effectiveness and significant toxicity, with existing antiviral compounds like ribavirin and interferon-alpha showing limited benefits and side effects.
Innovation Solution
Development of novel compounds of Formula I, which are administered to patients to reduce viral loads or clear RNA, providing a therapeutic option for Flaviviridae viral infections, including hepatitis C, by targeting specific viral mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ribavirin and interferon-alpha are used to treat HCV infections, then viral RNA levels are reduced, but treatment effectiveness is limited and significant toxicity occurs
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of antiviral compounds through various substitutions (R1, R2, R3, R4 groups) to optimize the balance between antiviral efficacy and toxicity. The compounds of Formula I represent a systematic exploration of structural parameters to achieve improved therapeutic profiles compared to existing ribavirin and interferon-alpha treatments.
2Reliability
If high doses of antiviral compounds are administered to overcome viral mutability, then viral load reduction is achieved, but treatment toxicity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical substituents (R1 as C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C3-12 cycloalkyl, C6-14 aryl, 3-14 membered heteroaryl, etc.) to optimize compound potency and selectivity. This structural optimization aims to achieve effective viral load reduction at lower, less toxic doses.
Solution Approach 2:
The patent creates composite molecular structures combining a core heterocyclyl or heteroaryl framework with various functional groups and substituents. This composite approach allows for fine-tuning of pharmacological properties to achieve both efficacy and reduced toxicity.
3Reliability
If combination therapy with interferon and ribavirin is used, then persistent benefit is achieved in some patients, but less than half of patients show improvement
Solution Approach 1:
The patent seeks to create a universal antiviral compound of Formula I that can effectively treat HCV infections across diverse patient populations. The compound is designed to target conserved viral mechanisms that are less susceptible to mutation, providing more consistent and predictable responses across different patients compared to existing combination therapies.
Data Source
AI summary
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.